市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 混合的 |
| Biotechnology (全球的) | 混合的 | 混合的 | |
| 股票 | PepGen Inc. | 看涨 | 看跌 |
AIStockmoo 评分
| 分析师共识 | 4.0 |
| 内部交易活动 | NA |
| 价格波动 | -2.0 |
| 技术平均移动指标 | 2.5 |
| 技术振荡指标 | 2.0 |
| 平均 | 1.63 |
|
PepGen Inc is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics to transform the treatment of severe neuromuscular and neurologic diseases. The company has developed its Enhanced Delivery Oligonucleotide platform to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake, and nuclear delivery, and in preclinical studies, it is observed their ability to transport oligonucleotides into a broad range of target tissues, including smooth, skeletal, and cardiac muscle and the central nervous system. Its pipeline products are; PGN-EDO51, PGN-EDODM1, and others including PGN-EDO53 and PGN-EDO45. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Core |
| 内部持股比例 | 0.27% |
| 机构持股比例 | 95.95% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Ikarian Capital, Llc | 30 Jun 2025 | 150,000 |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 12.00 (Stifel, 136.69%) | 购买 |
| 12.00 (HC Wainwright & Co., 136.69%) | 购买 | |
| 中 | 10.00 (97.24%) | |
| 低 | 6.00 (Guggenheim, 18.34%) | 购买 |
| 平均值 | 9.50 (87.38%) | |
| 总计 | 4 购买 | |
| 平均价格@调整类型 | 4.87 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| Wedbush | 30 Sep 2025 | 8.00 (57.79%) | 购买 | 5.07 |
| 25 Sep 2025 | 9.00 (77.51%) | 购买 | 5.88 | |
| HC Wainwright & Co. | 25 Sep 2025 | 12.00 (136.69%) | 购买 | 5.88 |
| Stifel | 25 Sep 2025 | 12.00 (136.69%) | 购买 | 5.88 |
| Guggenheim | 24 Sep 2025 | 6.00 (18.34%) | 购买 | 2.66 |
| 09 Sep 2025 | 6.00 (18.34%) | 购买 | 1.48 |
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合